

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



## **WING LEE HOLDINGS LIMITED**

**永利控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 876)**

### **INSIDE INFORMATION — DISPOSAL OF SHARES BY CONTROLLING SHAREHOLDER**

This announcement is made by Wing Lee Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

#### **DISPOSAL OF SHARES BY CONTROLLING SHAREHOLDER**

The Company has been informed by its controlling shareholder, Weltrade Group Limited (the “**Vendor**”), a company wholly-owned by Mr. Wen Jialong (“**Mr. Wen**”), the Chairman and an executive director of the Company, that it has, on 19 September 2014 (after trading hours of the Stock Exchange), entered into a unconditional sale and purchase agreement (the “**SPA**”) with Xiajian Advanced Technology Limited (the “**Purchaser**”), a company incorporated in the British Virgin Islands and which is wholly-owned by Mr. Xie Yuehui (“**Mr. Xie**”). Pursuant to the SPA, the Vendor has unconditionally agreed to sell, 93,000,000 shares of HK\$0.01 each (“**Shares**”) or 744,000,000 shares of HK\$0.00125 each (the “**Subdivided Shares**”) upon the share subdivision (the “**Share Subdivision**”) proposed by the Company on 15 August 2014 becoming effective, which is expected to be on 23 September 2014) in the share capital of the Company (representing approximately 29.01% of the issued share capital of the Company) to the Purchaser, for a total consideration of HK\$191,580,000, equivalent to HK\$2.06 per Share (or HK\$0.2575 per Subdivided Share, upon the Share Subdivision becoming effective) (the “**Disposal**”).

Pursuant to the SPA, the completion of the Disposal shall take place on 23 September 2014 (or such other day the parties may agree).

\* for identification purpose only

As at the date of this announcement, the Vendor is interested in 224,712,255 Shares (which represents approximately 70.11% of the issued share capital of the Company) owned by the Vendor. After the completion of the Disposal, Mr. Wen's shareholding interest in the Company will decrease to 131,712,255 Shares (or 1,053,698,040 Subdivided Shares upon the Share Subdivision becoming effective), which represents approximately 41.09% of the issued share capital of the Company, and the Purchaser will hold 93,000,000 Shares (or 744,000,000 Subdivided Shares, upon the Share Subdivision becoming effective) which represents approximately 29.01% of the issued share capital of the Company. Immediately after completion of the Disposal, the Vendor will remain to be a controlling shareholder (as defined in the Listing Rules) of the Company and the Purchaser will become a substantial shareholder (as defined in the Listing Rule) of the Company.

### **INFORMATION OF MR. XIE**

Mr. Xie, aged 45, is the chairman and has been appointed as a director of LifeTech Scientific Corporation (“**LifeTech**”), a company listed on the main board of the Stock Exchange (Stock Code: 1302) with principally activities of manufacturing and marketing of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders, with effect from August 2006 and as an director with effect from 22 October 2011. Mr. Xie is primarily responsible for our LifeTech's overall strategic planning and the management of LifeTech's business. Mr. Xie has 15 years experience in business management in medical device industry. Mr. Xie graduated from 昆明工學院 (Kunming Institute of Technology\*) in July 1991 with a bachelor's degree. He also obtained a master's degree from Tsinghua University in July 2006. Currently, Mr. Xie is currently standing vice president of the 中國醫療器械協會 (China Association for Medical Devices Industry\*) and chairman of 中國生物材料學會 (Chinese Society for Biomaterials\*). In 2014, Mr. Xie has earned 國家科技進步一等獎 (the National Science & Technology Progress Award (first class)\*) and 生物 — 生命健康產業創新成果金獎.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, the Purchaser and Mr. Xie are third parties independent of and not connected with the Company and its connected persons (as defined in the Listing Rule).

The Company will continue with its existing business after the Disposal. At the same time, the Company will keep on exploring other business diversification opportunities in order to enhance the long-term growth potential of the Company. It is expected that Mr. Xie will bring strategic value to the Company by his extensive experience in the medical industry.

By order of the Board  
**Wing Lee Holdings Limited**  
**Wen Jialong**  
*Chairman and Executive Director*

Hong Kong, 19 September 2014

*As at the date of this announcement, the Board comprises two executive directors, namely Mr. Wen Jialong (Chairman) and Mr. Wu Xiaolin (Vice-Chairman), two non-executive directors, namely Mr. Chow Tak Hung and Mr. Lam Kwok Cheong and three independent non-executive directors, namely Mr. Zeng Zhaolin, Dr. Loke Yu alias Loke Hoi Lam and Mr. Lung Chee Ming George.*

*\* For identification only*